Connecticut’s recent experience with legalization in 2021 provides a particularly relevant case study for understanding the outcomes and potential harms of liberalization. While advocates emphasize individual freedom, economic gains, and the medicinal potential, emerging research highlights significant risks, especially concerning mental health, addiction, and the vulnerability of younger populations. Drawing lessons from regions where the effects of legalization are already observable can help inform the ethical, legal, and scientific debate in Europe.
Across Europe, EU member states such as Czechia, Germany, Luxembourg, Malta, the Netherlands, and other non-EU countries, have legalized or plan to legalize recreational cannabis. In Central and Eastern Europe, however, skepticism towards legalization remains. Central Europe’s often methodical approach allows these nations to observe, analyze, and learn from early adopters’ experience without incurring its costs.
As Western reforms widen the policy gap across Europe, national policies like Hungary's, gain value. In 2025, Hungary strengthened its zero-tolerance drug policy through sweeping legal reforms aimed at protecting public health and reducing youth drug use. Under the new law, individuals caught with drugs can only avoid prosecution by cooperating with authorities and identifying their sources. The use and possession of designer drugs (synthetic substances or synthetic marijuana) are now fully criminalized due to their unpredictable and dangerous health effects. Penalties for possession, trafficking, and distribution are stricter, with prison sentences ranging from two to twenty years, including the confiscation of property used in drug-related crimes. Police may detain anyone under the influence in public for up to seventy-two hours if they pose a danger. Most importantly, a 2025 constitutional amendment explicitly bans the production, use, and promotion of drugs, making zero tolerance a constitutional principle. These measures underline Hungary’s preventive approach, aiming to shield citizens, especially the youth, from the growing mental health and social harms associated with drug use.
This can also be seen as a response to the rapid intensification of cannabis. THC concentrations have increased drastically, and new delivery modes (vaping, dabbing, concentrates, edibles) amplify dose, increasing the severity of use. These changes raise new concerns about neuropsychiatric risks, addiction, and life impairment.
Studies consistently document associations between heavy cannabis use and anxiety, depressive symptoms, and psychotic-like phenomena. In vulnerable individuals, frequent cannabis use may precipitate first-episode psychosis or aggravate existing psychiatric disorders. Once psychosis is present, continued cannabis use is linked to worse clinical outcomes including relapse, hospitalizations, cognitive impairment, and functional decline.
Cannabis risk is not uniform and certain demographic groups are more vulnerable. In Connecticut’s 2025 Cannabis Health Statistics Report, adult past-month users with poor mental health are more likely to use daily or near-daily than those without. Among adolescents, cannabis use is more common among students reporting depression or low academic performance. The report also finds that males, young adults, and non-Hispanic Black residents register disproportionately high rates of cannabis-related emergency department visits and hospitalizations.
The effect of cannabis use on the adolescent and maturing adult brain (up to age 25) carries higher risk. Disruptions from exogenous cannabinoids may impair synaptic pruning, connectivity, and executive networks, increasing vulnerability to cognitive and emotional dysfunction.
Addiction is also a real threat. Estimates suggest around 9% of occasional users and up to 17% of adolescent users develop cannabis use disorder (CUD). Substance use disorders rarely occur in isolation: it is entwined with mood disorders, anxiety, lower academic and professional achievement, and social impairment. Recreational use can serve as a gateway to heavier dependence, especially in susceptible individuals.
There are understandable drivers behind calls for cannabis liberalization. Regulated markets can impose testing, labeling, age limits, and reduce black market risks. Tax revenues may support health, education, or treatment programs. Medical cannabis, under supervision, has demonstrated benefits for select conditions like chronic pain, spasticity or chemotherapy-induced nausea. However, recreational cannabis remains a psychoactive drug, not a benign wellness substance.
Legalization can problematically shift norms toward greater acceptance and more frequent use. Normalization dangerously masks the path from recreational to problematic use. Monitoring, early intervention, treatment accessibility, and harm-reduction infrastructure must accompany any legal regime.
Connecticut provides a unique example on the effects of legalization. The U.S. state legalized adult recreational cannabis on July 1, 2021, with sales starting in 2023. The state now publishes the annual Cannabis Health Statistics which utilizes multiple databases to monitor trends.
Key findings from 2025 include:
- Adult past-month use has increased, particularly in ages 18–34.
- Smoking remains the dominant mode (70.5%), though vaping, dabbing, and edibles are common.
- About 1 in 4 adult users drove within three hours of consumption, a serious public safety warning.
- Among adolescents, lifetime and past-month use correlate with poor academic performance and depression.
- Although total cannabis-related hospital visits have declined slightly, rates remain elevated among males and non-Hispanic Black residents.
- Poison control center calls involving children are striking: more than 668 calls since 2019 for those under age 18.
- The average price per cannabis product in the adult-use market has declined over 2025 (e.g. from ~$37.24 in January to ~$32 in September), signaling supply expansion or competition.
These observations do not prove causality, but they flag domains that require granular, prospective tracking: usage escalation, youth exposure, traffic safety, demographic disparities, and shifts in harm presentation.
The liberalization of cannabis policy embodies a defining trend of our time, driven predominantly by ideological forces championing individual liberties, economic incentives, and progressive harm-reduction paradigms. This ongoing trend shows no signs of slowing, with countries like Germany's partial decriminalization and global projections of rapid market expansion. Despite Hungary's robust zero-tolerance policy, it remains exposed to broader influences, including shifting societal attitudes and transnational exchanges. Such developments demand vigilant, evidence-based responses, especially given marijuana's well-documented risks, from heightened chances of anxiety and dependence to potential cognitive impairments and psychotic episodes, particularly among younger or vulnerable users, underscoring the need for policies that prioritize long-term public health.
In this landscape, empirical studies from states like Connecticut are critically important. Rather than absorbing dominant narratives, for or against liberalization, policymakers must prioritize evidence from real-world implementations. Connecticut's regulated system, now four years old, offers tangible data on usage trends, health outcomes, and societal impacts, enabling Central and Eastern Europe to anticipate challenges without hasty adoption. By grounding decisions in such insights, these nations can safeguard public health, preserve community resilience, and craft measures that align with their priorities, potentially exploring limited medical frameworks while maintaining robust protections against recreational risks.
-
https://www.euda.europa.eu/system/files/documents/2023-06/20232262_pdf_td0923192enn_002.pdf
https://www.mpp.org/states/connecticut/
https://insideinvestigator.org/recreational-cannabis-prices-continue-to-fall/
